NCT04825587

Brief Summary

The overall aim of this multicenter RCT is to determine whether concomitant ALL reconstruction in children undergoing and ACL reconstruction will longitudinally result in a lower rate of graft failure than ACL reconstruction alone.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
240

participants targeted

Target at P75+ for not_applicable

Timeline
23mo left

Started Apr 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress73%
Apr 2021Apr 2028

First Submitted

Initial submission to the registry

March 29, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 1, 2021

Completed
27 days until next milestone

Study Start

First participant enrolled

April 28, 2021

Completed
6.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2028

Last Updated

November 15, 2024

Status Verified

November 1, 2024

Enrollment Period

6.9 years

First QC Date

March 29, 2021

Last Update Submit

November 14, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Graft failure

    To determine whether concomitant ALL reconstruction in children undergoing and ACL reconstruction will longitudinally result in a lower rate of graft failure (confirmed graft re-tear or asymmetric, increased pivot shift) than ACL reconstruction alone.

    Complete when all 780 participants have been recruited, received an intervention and have been followed for data collection for up to 5 years.

Secondary Outcomes (2)

  • Complications of ALL reconstruction

    Complete when all 780 participants have been recruited, received an intervention and have been followed for data collection for up to 5 years.

  • Patient reported outcome measures

    Complete when all 780 participants have been recruited, received an intervention and have been followed for data collection for up to 5 years.

Study Arms (2)

Concomitant ACL and ALL reconstruction

EXPERIMENTAL

The participant will undergo both the ACL and ALL reconstruction surgery.

Procedure: Patients will be randomized into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone.

ACL reconstruction alone

EXPERIMENTAL

The participant will undergo only ACL reconstruction surgery.

Procedure: Patients will be randomized into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone.

Interventions

By randomizing patients into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone, following statistical analysis, we hope to determine whether concomitant ALL reconstruction in children undergoing and ACL reconstruction will longitudinally result in a lower rate of graft failure than ACL reconstruction alone.

ACL reconstruction aloneConcomitant ACL and ALL reconstruction

Eligibility Criteria

AgeUp to 18 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Age 18 and under
  • Surgery within 6 months of injury
  • Undergoing primary ACL reconstruction without previous injury or surgery
  • Quadriceps tendon autograft ACL reconstruction
  • Closing or closed physes

You may not qualify if:

  • Over 18 years old
  • Previous ipsilateral knee injury or surgery
  • Neuromuscular or developmental disorders affecting knee anatomy, cognition, or neuromuscular control
  • Other concomitant ligament reconstruction aside from the ALL (i.e., MCL, PCL, PLC)
  • Revision ACL reconstruction
  • ACL reconstruction with graft other than quadriceps tendon
  • IT band (modified MacIntosh) ACL reconstruction
  • A cartilage lesion requiring anything more than debridement
  • Open physes requiring both femoral and tibial physeal-sparing technique

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Lurie Children's Hospital

Chicago, Illinois, 60611, United States

RECRUITING

MeSH Terms

Conditions

Anterior Cruciate Ligament Injuries

Condition Hierarchy (Ancestors)

Knee InjuriesLeg InjuriesWounds and Injuries

Study Officials

  • Neeraj Patel, MD

    Lurie Children's Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: The overall aim of this multicenter RCT is to determine whether concomitant ALL reconstruction in children undergoing and ACL reconstruction will result in a lower rate of graft failure than ACL reconstruction alone.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, Orthopedic Surgery & Sports Medicine, Surgery

Study Record Dates

First Submitted

March 29, 2021

First Posted

April 1, 2021

Study Start

April 28, 2021

Primary Completion (Estimated)

April 1, 2028

Study Completion (Estimated)

April 1, 2028

Last Updated

November 15, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will share

Collected Participant info that may be collected and shared :Personal and health information, Past/present medical records, Records from study visits/phone calls. Behavioral or mental health info about the participants will be collected and may be shared.The study staff, employees, and Medical Staff of Lurie Children's may use participant's info for this study and share it with study sponsor, POSNA and those working with the sponsor, IRB, Participant's other providers and their staff directly involved in their care, if their provider is a part of the Lurie Children's electronic health information exchange: The Office of Human Research Protections (OHRP), the Food and Drug Administration (FDA), or other government offices. We cannot guarantee that those listed above will not share it with others without participant's permission. Participant's names will not be included in any written or verbal reports of study results.

Shared Documents
STUDY PROTOCOL, ICF
Time Frame
from the study start up/participant recruitment (beginning April 2021) until 1/1/2030
Access Criteria
Study personnel only

Locations